证券之星消息，截至2026年2月25日收盘，英科医疗(300677)报收于41.75元，上涨0.48%，换手率 1.35%，成交量6.27万手，成交额2.62亿元。 2月25日的资金流向数据方面，主力资金净流出3192.88万元，占总成交额12.16%，游资资金净流出 1653.63万元，占总成交额6.3%，散户资金净流入4846.51万元，占总成交额18.47%。 该股最近90天内共有4家机构给出评级，买入评级4家。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 该股主要指标及行业内排名如下： 英科医疗 ...

Core Viewpoint - The stock of Yingke Medical (300677) has shown a decline in price and mixed financial performance, with a notable increase in net profit but a decrease in revenue in the latest quarter [1][2]. Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 7.425 billion yuan, an increase of 4.6% year-on-year [2]. - The net profit attributable to shareholders reached 924 million yuan, reflecting a significant increase of 34.47% year-on-year [2]. - The net profit excluding non-recurring items was 484 million yuan, which represents a decline of 19.32% year-on-year [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 2.511 billion yuan, down 2.9% year-on-year [2]. - The single-quarter net profit attributable to shareholders was 214 million yuan, showing a remarkable increase of 113.04% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was 84.28 million yuan, down 25.87% year-on-year [2]. - The company's debt ratio stands at 53.79%, with investment income of 183 million yuan and financial expenses of 127 million yuan [2]. - The gross profit margin is reported at 23.7% [2]. Stock Performance and Market Sentiment - As of February 13, 2026, the stock closed at 39.35 yuan, down 1.82%, with a turnover rate of 1.07% and a trading volume of 49,900 hands, amounting to a transaction value of 198 million yuan [1]. - The net outflow of main funds was 938,000 yuan, accounting for 0.47% of the total transaction value, while retail investors saw a net inflow of 2.7368 million yuan, representing 1.38% of the total transaction value [1]. - Over the last 90 days, four institutions have given buy ratings for the stock [3].

Core Viewpoint - As of February 12, 2026, Yingke Medical (300677) closed at 40.08 yuan, down 2.6%, with a turnover rate of 1.46% and a trading volume of 68,000 hands, amounting to a transaction value of 274 million yuan [1] Group 1: Market Performance - On February 12, 2026, the net outflow of main funds was 25.52 million yuan, accounting for 9.31% of the total transaction value, while retail investors saw a net inflow of 31.69 million yuan, representing 11.56% of the total transaction value [1] - Over the past five days, the stock has experienced fluctuations in net fund flows, with notable outflows on February 9 and February 12, and a net inflow from retail investors on February 12 [2] Group 2: Financing and Margin Trading - On February 12, 2026, the financing buy-in was 19.75 million yuan, while the financing repayment was 28.53 million yuan, resulting in a net repayment of 8.78 million yuan [2] - The margin trading balance stood at 503 million yuan, with a short selling volume of 3,100 shares and a remaining short selling balance of 9.41 million yuan [3] Group 3: Company Financials and Industry Comparison - Yingke Medical's total market capitalization is 26.207 billion yuan, with a net asset value of 18.467 billion yuan and a net profit of 924 million yuan, ranking 8th, 4th, and 7th respectively in the medical device industry [5] - The company reported a year-on-year revenue increase of 4.6% to 7.425 billion yuan for the first three quarters of 2025, with a net profit increase of 34.47% to 924 million yuan [5] - The gross profit margin is 23.7%, which is significantly lower than the industry average of 51.01%, indicating potential areas for improvement [5]

Core Viewpoint - The financial performance of Yingke Medical (300677) shows mixed results, with a slight increase in revenue but a significant rise in net profit, indicating potential growth opportunities despite some declines in specific metrics [2]. Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 7.425 billion yuan, an increase of 4.6% year-on-year [2]. - The net profit attributable to shareholders reached 924 million yuan, reflecting a substantial increase of 34.47% year-on-year [2]. - The net profit excluding non-recurring items was 484 million yuan, which represents a decline of 19.32% year-on-year [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 2.511 billion yuan, down 2.9% year-on-year [2]. - The single-quarter net profit attributable to shareholders was 214 million yuan, showing a remarkable increase of 113.04% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was 84.28 million yuan, down 25.87% year-on-year [2]. - The company's debt ratio stands at 53.79%, with investment income of 183 million yuan and financial expenses of 127 million yuan [2]. - The gross profit margin is reported at 23.7% [2]. Stock Performance and Market Sentiment - As of February 6, 2026, the stock closed at 41.36 yuan, with an increase of 1.03% and a turnover rate of 1.6% [1]. - The trading volume was 74,400 hands, with a total transaction value of 309 million yuan [1]. - On February 6, the net inflow of main funds was 3.0677 million yuan, accounting for 0.99% of the total transaction value [1]. - The net inflow of speculative funds was 6.9237 million yuan, representing 2.24% of the total transaction value [1]. - Retail investors experienced a net outflow of 9.9914 million yuan, which is 3.23% of the total transaction value [1]. - Over the last 90 days, six institutions have provided ratings for the stock, with five giving a buy rating and one an increase rating [3].

Core Viewpoint - As of February 5, 2026, Yingke Medical (300677) closed at 40.94 yuan, experiencing a slight decline of 0.46% with a trading volume of 57,100 hands and a transaction amount of 233 million yuan [1] Financial Performance - For the first three quarters of 2025, Yingke Medical reported a main revenue of 7.425 billion yuan, an increase of 4.6% year-on-year; net profit attributable to shareholders was 924 million yuan, up 34.47% year-on-year; however, the net profit excluding non-recurring items decreased by 19.32% to 484 million yuan [2] - In Q3 2025, the company recorded a single-quarter main revenue of 2.511 billion yuan, down 2.9% year-on-year; single-quarter net profit attributable to shareholders was 214 million yuan, an increase of 113.04% year-on-year; single-quarter net profit excluding non-recurring items was 84.28 million yuan, down 25.87% year-on-year [2] - The company's debt ratio stands at 53.79%, with investment income of 183 million yuan and financial expenses of 127 million yuan; the gross profit margin is reported at 23.7% [2] Market Sentiment - Over the last 90 days, six institutions have provided ratings for the stock, with five giving a "buy" rating and one an "increase" rating [3]

Core Viewpoint - The stock of Yingke Medical (300677) has shown a slight increase, with a closing price of 40.55 yuan on February 3, 2026, reflecting a 1.38% rise, amidst mixed capital flows from different investor types [1]. Group 1: Stock Performance and Capital Flow - On February 3, 2026, the stock recorded a trading volume of 61,800 hands and a total transaction amount of 250 million yuan [1]. - The net inflow of main funds was 4.6573 million yuan, accounting for 1.86% of the total transaction amount, while retail investors experienced a net outflow of 8.2815 million yuan, representing 3.31% of the total [1][2]. - Over the past five days, the stock has seen fluctuations in capital flow, with significant net inflows and outflows from both main and retail investors [2]. Group 2: Financial Metrics and Industry Ranking - Yingke Medical has a total market value of 26.567 billion yuan, ranking 8th in the medical device industry, which has an average market value of 10.943 billion yuan [3]. - The company reported a net profit of 924 million yuan, which is 34.47% higher year-on-year, while its main revenue for the first three quarters of 2025 was 7.425 billion yuan, up 4.6% year-on-year [3]. - The company's gross profit margin stands at 23.7%, significantly lower than the industry average of 50.55%, indicating potential areas for improvement [3]. Group 3: Analyst Ratings - In the last 90 days, six institutions have provided ratings for Yingke Medical, with five giving a "buy" rating and one an "accumulate" rating, reflecting a generally positive outlook from analysts [4].

证券之星消息，截至2026年1月30日收盘，英科医疗(300677)报收于41.86元，上涨2.57%，换手率 2.51%，成交量11.71万手，成交额4.81亿元。 1月30日的资金流向数据方面，主力资金净流入1347.49万元，占总成交额2.8%，游资资金净流入 2536.19万元，占总成交额5.27%，散户资金净流出3883.69万元，占总成交额8.07%。 | 指标 | 英科医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 274.25亿元 | 111.02亿元 | 7 127 | | 净资产 | 184.67亿元 | 38.45亿元 | 4 127 | | 净利润 | 9.24亿元 | 2.1亿元 | 7 127 | | 市盈率(动) | 22.25 | 104.17 | 16 127 | | 市净率 | 1.51 | 4.04 | 18 127 | | 毛利率 | 23.7% | 50.94% | 117 127 | | 净利率 | 12.82% | 9.66% | 54 127 | | ROE | 5.19% | 0.43% | 5 ...

Group 1 - The core viewpoint of the news is that Yingke Medical (300677) has shown a mixed financial performance in recent quarters, with a notable increase in net profit but a decline in revenue for the latest quarter [2] - As of January 19, 2026, Yingke Medical's stock closed at 42.0 yuan, with a 1.23% increase and a trading volume of 10.38 million shares, resulting in a transaction value of 437 million yuan [1] - The company reported a total revenue of 7.425 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 4.6%, while the net profit attributable to shareholders was 924 million yuan, up 34.47% year-on-year [2] Group 2 - In Q3 2025, the company's revenue was 2.511 billion yuan, showing a decline of 2.9% year-on-year, while the net profit for the same quarter was 214 million yuan, which represents a significant increase of 113.04% year-on-year [2] - The company's debt ratio stands at 53.79%, with investment income of 183 million yuan and financial expenses of 127 million yuan, leading to a gross profit margin of 23.7% [2] - Over the past 90 days, 9 institutions have rated the stock, with 8 giving a buy rating and 1 an increase rating, and the average target price set by institutions is 46.25 yuan [2]

Core Viewpoint - As of October 30, 2025, Yingke Medical (300677) closed at 39.33 yuan, marking a 1.08% increase, with a trading volume of 187,700 hands and a transaction value of 748 million yuan [1] Financial Performance - For the first three quarters of 2025, Yingke Medical reported a main business revenue of 7.425 billion yuan, a year-on-year increase of 4.6% - The net profit attributable to shareholders was 924 million yuan, up 34.47% year-on-year - The net profit after deducting non-recurring gains and losses was 484 million yuan, down 19.32% year-on-year - In Q3 2025, the company recorded a single-quarter main business revenue of 2.511 billion yuan, a year-on-year decrease of 2.9% - The single-quarter net profit attributable to shareholders was 214 million yuan, up 113.04% year-on-year - The single-quarter net profit after deducting non-recurring gains and losses was 84.28 million yuan, down 25.87% year-on-year - The company's debt ratio stood at 53.79%, with investment income of 183 million yuan and financial expenses of 127 million yuan [3] Market Position - Yingke Medical's total market value is 25.753 billion yuan, ranking 8th in the medical device industry - The company's net assets amount to 18.467 billion yuan, ranking 4th in the industry - The net profit of 924 million yuan places it 7th in the industry - The price-to-earnings ratio (P/E) is 20.89, significantly lower than the industry average of 60.08, ranking 11th - The price-to-book ratio (P/B) is 1.42, also lower than the industry average of 3.86, ranking 17th - The gross margin is 23.7%, which is below the industry average of 51.22%, ranking 115th - The net margin is 12.82%, above the industry average of 9.57%, ranking 53rd - The return on equity (ROE) is 5.19%, significantly higher than the industry average of 0.15%, ranking 53rd [3] Recent Trading Activity - On October 30, 2025, the net inflow of main funds was 11.2932 million yuan, accounting for 1.51% of the total transaction value - The net inflow of speculative funds was 27.5105 million yuan, accounting for 3.68% of the total transaction value - Retail investors experienced a net outflow of 38.8037 million yuan, accounting for 5.18% of the total transaction value - Over the past five days, the stock has seen fluctuations in fund flows, with notable net outflows on October 28 and October 29, and a significant net inflow on October 27 [1][2]

Core Viewpoint - As of October 29, 2025, Yingke Medical (300677) closed at 38.91 yuan, with a slight increase of 0.91% and a trading volume of 15.34 million shares, amounting to a total transaction value of 5.91 billion yuan [1] Financial Performance - For the first three quarters of 2025, Yingke Medical reported a main business revenue of 7.425 billion yuan, a year-on-year increase of 4.6%, and a net profit attributable to shareholders of 924 million yuan, up 34.47% year-on-year [3] - The third quarter of 2025 saw a single-quarter main business revenue of 2.511 billion yuan, a decrease of 2.9% year-on-year, while the single-quarter net profit attributable to shareholders was 214 million yuan, an increase of 113.04% year-on-year [3] - The company’s gross profit margin stands at 23.7%, with a net profit margin of 12.82% [3] Market Position - Yingke Medical has a total market capitalization of 25.478 billion yuan, ranking 8th in the medical device industry [3] - The company’s price-to-earnings ratio (P/E) is 20.67, significantly lower than the industry average of 59.7, ranking 11th in the industry [3] - The company’s return on equity (ROE) is 5.19%, which is higher than the industry average of 2.88%, ranking 46th in the industry [3] Capital Flow Analysis - On October 29, 2025, the net outflow of main funds was 20.3013 million yuan, accounting for 3.43% of the total transaction value, while retail investors saw a net inflow of 57.8882 million yuan, representing 9.79% of the total transaction value [1][2] - Over the past five days, the stock has experienced fluctuations in capital flow, with significant net outflows from main and speculative funds on several days [2]